VEGFA and oropharyngeal carcinoma: Furthermore, RRM2 can enhance angiogenesis by upregulating VEGF in oropharyngeal carcinoma cells, and thus anti-angiogenic and anti-tumor effects are anticipated following RRM2 inhibition [27].